Introduction
Acute liver failure (ALF)
Definition
Liver failure | Defined by | Subtypes/classification | Incidence (% ICU patients) | Mortality (28 and 90 day) | Prognostic clinical features | Cutoff for mortality increase |
---|---|---|---|---|---|---|
ALF | Hepatic Encephalopathy Coagulopathy: INR > 1.5 Absence of previous liver injury Duration < 26 weeks | According to the interval from jaundice to HE appearance: Bernuau: Fulminant: < 2 weeks Subfulminant: 2–12 weeks O´Grady: Hyperacute: < 1 week Acute: 1–4 weeks Subacute: 5–12 weeks Japanese consensus (if HE < II: without hepatic coma; If HE ≥ grade II: with hepatic coma): Fulminant: 0–8 weeks Acute: 0–10 days Subacute: 11–56 days LOHF: > 56 days | < 1% | Up to 50% | Grade of HE | Acute/hyperacute versus subacute/LOHF |
Extrahepatic organ failure | AKI | |||||
Age | < 10 or > 40 years | |||||
Lactate | ≥ 4 mmol/l | |||||
Bilirubin (non-paracetamol) | > 17 mg/dl | |||||
Arterial ammonia | > 100 µmol/l | |||||
ACLF | EASL: Acute deterioration: Usually related to a precipitating event From extrahepatic origin or Secondary to superimposed liver injury Preexisting liver disease: Chronic liver disease High 90-day mortality due to multisystem organ failure | According to the presence of extrahepatic failure: ACLF 1: Single kidney failure, or Single liver/coagulation/circulatory/respiratory failure and SCr: 1.5–1.9 mg/dl or Mild-to-moderate HE, or Single cerebral failure and SCr 1.5 mg/dl ACLF 2: 2 organ failures ACLF 3: ≥ 3 organ failures | 1–5% (24–40% of patients with cirrhosis admitted to hospital) | 28-day: 34% ACLF 1: 22% ACLF 2: 32% ACLF 3: 77% 90-day: 51% ACLF 1: 41% ACLF 2: 52% ACLF 3: 79% | Bilirubin | 6–12 mg/dl |
HE | Grade I-II | |||||
INR | 2.0–2.5 | |||||
MAP | < 70 mmHg | |||||
Creatinine | 2.0 mg/dl in single kidney failure, or 1.5–1.9 mg/dl in single non-kidney organ failure | |||||
Age | ||||||
WBC count | Infection [6] | |||||
Number of organ failures | ≥ 2 | |||||
Respiratory function | PaO2/FiO2: 200–300, or SpO2/FiO2: 214–357 | |||||
NACSELD: Cirrhosis and two extrahepatic organ failures Organ failures are defined as (1) Shock (2) Grade III/IV hepatic encephalopathy (HE) (3) Need for dialysis (4) Mechanical ventilation | N.a | N.a | According to the number of organ failure and infection 1 OF: 10%/20% 2 OF: 16%/38% 3 OF: 35%/58% ≥ 4 OF: 0%/76% | Number of organ failure | ≥ 2 | |
APASL: Acute hepatic insult: Jaundice: bilirubin ≥ 5 mg/dL Coagulopathy: INR ≥ 1.5 or PT activity < 40% Complicated within 4 weeks by Ascites and/or HE Preexisting liver failure: Diagnosed or undiagnosed Chronic liver disease/cirrhosis High 28-day mortality Organ failure other than liver is not part of the definition | According to AARC Score [47], which defines the grade of liver failure: Grade I (mild): 5–7 Grade II (severe): 8–10 Grade III (very severe): 11–15 | 1–5% (24–40% of patients with cirrhosis admitted to hospital) | 28-day: 33–44% Grade I: 12.7% Grade II: 44.5% Grade III: 85.9% 90 day: 47–53% | HE | Grade III-IV | |
Infection | ||||||
INR | 1.8–2.5 | |||||
Lactate | 1.5–2.5 mmol/l | |||||
Creatinine | 1.1–1.5 mg/dl or AKIN Stage 1 | |||||
Age | ||||||
WBC count | ||||||
Obesity | ||||||
“Golden window” | Sepsis, MOF | |||||
Secondary Acquired Liver Injury | Cholestasis: Altered bile excretion, synthesis or secretion Bilirubin > 2 mg/dl (no consensus exist) | According to the mechanism: Extrahepatic Intrahepatic | 11–36% | 27–48% | Bilirubin Bile acids Concomitant syndromes | > 2 mg/dl ≥ 5.2 µmol/l increase Sepsis |
Hypoxic Liver Injury: Respiratory, cardiogenic or circulatory shock Elevation of transaminases > 20-fold from the reference value Absence of underlying liver injury | According to precipitating event: Sepsis Cardiogenic shock Parenteral nutrition | 10% | 40–60% | SOFA score: INR Peak arterial ammonia ICG-PDR Concomitant syndromes | ≥ 11 > 2 > 75 µmol/l < 9%/min Sepsis |
Incidence and mortality
Prognostic clinical features
-
Hepatic encephalopathy HE remains the essential clinical hallmark, and its presence, even at low grade, is indicative of poor prognosis [1]. HE is primarily a clinical diagnosis. The joint EASL/AASLD guidelines suggest that if ammonia levels are normal, the diagnosis of HE is in question [32]. EEG provides information on the severity of HE in both cooperative and especially in uncooperative patients but is nonspecific [33]. Arterial ammonia concentration in whole blood on admission to the ICU is an independent risk factor for both encephalopathy and intracranial hypertension [34].
-
Severity of liver injury (reflected in prothrombin time or bilirubin) Changes in coagulation factors, such as INR, reflecting injury to the hepatocellular synthesis machinery, are of prognostic value. Similarly, serum bilirubin, reflecting injury to the excretory machinery of the hepatocyte, serves as a prognostic marker in ALF of non-paracetamol etiology, but has no value in paracetamol-induced ALF or even other causes of hyperacute liver failure due to the time required for bilirubin levels to build up [37].
-
Other factors These may include age (e.g., < 10 or > 40 years) and lactate levels (e.g., > 4 mmol/l), as indicated in the King’s College Criteria or the recent guidelines in the UK for the assessment of the need for LTx [2, 38]. Lactate, together with bilirubin and etiology, is part of the BiLE score, which has recently shown a good predictive value in a cohort of 102 ALF patients [37]. Other scoring systems are available for rare diseases, for example, the TIPS-BSC prognostic index [39].
Acute-on-chronic liver failure (ACLF)
Definition
Score | Use | Range | Definition of organ failure | Predicted mortality | References | |||||
---|---|---|---|---|---|---|---|---|---|---|
Liver | Kidney | Coagulation | Respiratory | Circulatory | CNS | |||||
APACHE-II | Assess the baseline risk groups being compared in clinical trials and determine prognosis on all patients newly admitted to the ICU | 0–77 | Cirrhosis | Need for dialysis | – | severe exercise restriction or respiratory dependency | NYHA Class IV | Based on GCS | 10: 15% 20: 40% > 34: 85% | [121] |
Components: | History of severe organ failure (Heart Failure Class IV; cirrhosis; chronic lung disease, or dialysis-dependent); Age; Temperature; MAP; pH; Heart rate/pulse; Respiratory rate; Sodium: Potassium; Creatinine; Acute renal failure; Hematocrit; White blood cell count; GCS; and FiO2 | |||||||||
SOFA | Determine level of organ dysfunction and mortality risk in ICU patients | 0–24 | Bilirubin ≥ 6 mg/dl | Creatinine ≥ 3.5 mg/dl | Plat < 50,000 | PaO2/FiO2 < 200 and MV | High-dose vasopressors | GCS < 13 | 6: 21% 10: 50% > 14: 95% | [12] |
Components: | FiO2/PaO2 (and MV); Platelets; GCS; Bilirubin; MAP (use of vasopressors); and Creatinine (or urine output) | |||||||||
CLIF-SOFA | Modified SOFA score, which had been specifically developed for the CANONIC study with patients with cirrhosis hospitalized for an acute decompensation | 0–24 | Bilirubin ≥ 12 mg/dl | Creatinine ≥ 2.0 mg/dl | INR ≥ 2.5 | PaO2/FiO2 < 200 or SpO2/FiO2 < 214 | Use of dopamine, dobutamine or terlipressin | HE ≥ III | See SOFA Score | [6] |
Components: | FiO2/PaO2 or SpO2/PaO2 (and MV); INR; Hepatic Encephalopathy; Bilirubin; MAP (use of vasopressors); and Creatinine (or urine output) | |||||||||
CLIF-C OF and CLIF-C ACLF | CLIF-C OF: Simpler and validated organ failure score for the diagnosis and grading of ACLF CLIF-C ACLF: Specific prognostic score for ACLF obtained from the combination of CLIF-C OF, age and white blood cell count | 6–18 | Bilirubin ≥ 12 mg/dl | Creatinine ≥ 2.0 mg/dl | INR ≥ 2.5 | PaO2/FiO2 < 200 or SpO2/FiO2 < 214 | Use of vasopressors | HE ≥ III | ACLF 1: 22% ACLF 2: 32% ACLF 3: 77% | [51] |
Components: | CLIF-C OF: Bilirubin; Creatinine; Need for RRT; HE Grade; INR, MAP (use of vasopressors); FiO2/PaO2 or SpO2/PaO2 (and MV) CLIF-C ACLF: Age; White blood cell count; and CLIF-C OF score | |||||||||
AARC ACLF | Prognostication and timely referral for liver transplantation. The score grades liver failure. The cutoff values for each system failure in this table are based on the definition of the APASL | 5–15 | Bilirubin ≥ 5 mg/dl | AKIN criteria: Creatinine: increase ≥ 0.3 mg/dL, or ≥ 1.5–2 × from baseline Urine output < 0.5 mL/kg per hour for > 6 h | INR ≥ 1.5 | – | – | HE ≥ III | 5–7: 12.7% 8–10: 44.5% 11–15: 85.9% | [47] |
Components: | Bilirubin, HE Grade, INR, Lactate, Creatinine | |||||||||
NACSELD ACLF | Facilitate prognosis determination in both infected and uninfected individuals with cirrhosis | Cirrhosis | Need for RRT | – | Need for MV | Shock: MAP < 60 mmHg | HE ≥ III | 1 OF: 37% 2 OF: 49% 3 OF: 64% ≥ 4 OF: 77% | [45] | |
Components: | Cirrhosis; Need for RRT; Need for MV; MAP; and HE | |||||||||
MELD | Determine prognosis and prioritize receipt of liver transplantation | 6–40 | The MELD score does not define the severity of different organ systems. It is less accurate for mortality prognosis than other scores | [122] | ||||||
Components: | Need for dialysis; Creatinine; Bilirubin; and INR | |||||||||
MELD-Na | The MELD-Na may improve upon the MELD score for liver cirrhosis | 6–40 | The MELD-Na score does not define the severity of different organ systems. The MELD-Na has been found to have a better fit for mortality prediction compared to the MELD score alone | 20: 4% 26: 15% > 32: 65% | [123] | |||||
Components: | Need for dialysis; Creatinine; Bilirubin; INR; and Sodium | |||||||||
Child–Pugh | Prognosis of patients with cirrhosis | 5–15 | The Child–Pugh score does not define the severity of different organ systems apart from liver. More recent scores like the MELD score and MELD-Na have become more used given their better prognostic value | |||||||
Components: | Bilirubin; Albumin; INR; Ascites; HE |
Incidence and mortality
Prognostic clinical features
Secondary acquired liver injury
Definition
Incidence and mortality
Prognostic clinical features
Study | Year | Bilirubin cutoff (mg/dl) | Population | Sample size | Incidence % | Mortality % | OR | 95% CI | p | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Liver dysfunction/cholestasis | |||||||||||
Harbrecht [80] | 2002 | 2 | Trauma | 2857 | 7.6 | 17.0 | 3.25 | 1.42–7.45 | 0.005 | ||
Krammer [56] | 2007 | 2 | ICU | 38,036 | 10.9 | 23.4 | 1.86 | 1.71–2.03 | < 0.001 | ||
1–2 | 19.3 | 21.3 | 1.24 | 1.14–1.34 | < 0.001 | ||||||
2–3 | 5.4 | 26.7 | 1.494 | 1.31–1.70 | < 0.001 | ||||||
3–6 | 4.3 | 33.3 | 2.228 | 1.94–2.55 | < 0.001 | ||||||
6–10 | 1.5 | 38.5 | 2.604 | 2.10–3.23 | < 0.001 | ||||||
> 10 | 1.0 | 46.8 | 3.991 | 3.10–5.13 | < 0.001 | ||||||
Jäger [76] | 2012 | 3 | Hypoxic liver injury | 175 | 36.0 | 64.0 | 2.195** | 1.17–4.12 | 0.014 | ||
Bingold [17] | 2015 | 1.2 | ICU | 23,795 | 19.0 | N.d | 1.335 | 1.22–1.47 | < 0.001 | ||
Dizier [84] | 2015 | 2 | ARDS | 805 | 17.6 | 52.1 | 1.43 | 1.28–1.61 | < 0.001 | ||
Guo [126] | 2015 | 2* | Intra-abdominal infection | 353 | 41.6 | 38.8 | 8.185 | 3.36–19.94 | < 0.001 | ||
Diab [79] | 2017 | 1.2 | Infective endocarditis | 285 | 23.9 | 51.5 | 5.00 | 2.48–10.06 | < 0.001 | ||
Salojee [81] | 2017 | 2 | Trauma | 225 | 21.3 | 31.3 | Not significant | ||||
Pierrakos [117] | 2017 | 1.1–2.0 | Infection | 8973 | 16.9 | 29 | 1.38 | 1.18–1.62 | < 0.001 | ||
2.1–6.0 | 7.8 | 40 | 1.71 | 1.38–2.12 | < 0.001 | ||||||
> 6 | 6.5 | 31 | 1.54 | 1.20–1.97 | < 0.001 | ||||||
Han [116] | 2021 | 12–15 | Extreme hyperbilirubinemia (≥ 12 mg/dl) | 1946 | 5.7 | 62.2 | Control | Control | Control | ||
15–20 | 5.1 | 71.7 | 1.543 | 0.76–3.14 | < 0.001 | ||||||
20–30 | 6.7 | 81.7 | 2.714 | 1.33–5.55 | < 0.001 | ||||||
≥ 30 | 0.4 | 90.7 | 5.935 | 2.17–16.20 | < 0.001 | ||||||
Bisbal [83] | 2021 | 2 | Hematologic malignancy | 893 | 20.7 | 45.4 | 2.26 | 1.62–3.14 | < 0.001 | ||
Juschten [82] | 2022 | 2*** | Sepsis | 4836 | 11.6 | 34.0 | 1.31 | 1.06–1.60 | 0.018 | ||
Hypoxic liver injury | |||||||||||
Fuhrmann [77] | 2011 | > 20-fold TA | ICU | 1066 | 11.1 | 57.0 | 4.62 | 3.63–5.86 | < 0.001 | ||
Champigneulle [127] | 2016 | > 20-fold TA | Out of hospital CA | 632 | 11.4 | 86.1 | 4.39 | 1.71–11.26 | < 0.01 | ||
Jung [128] | 2017 | > 20-fold TA | Cardiogenic shock | 172 | 18.0 | 68.0 | 2.52 | 1.30–4.90 | < 0.001 | ||
Iesu [129] | 2018 | > 20-fold TA | Resuscitated after CA | 374 | 7.2 | 89.0 | 16.28**** | 2.62–81.34 | 0.003 | ||
Van den broecke [70] | 2018 | > 5 AST | ICU | 1116 | 1.3 | 33.2 | Not documented | ||||
> 10 AST | 0.9 | 44.4 | |||||||||
> 20 AST | 1.5 | 55.4 | |||||||||
Jonsdottir [69] | 2022 | > tenfold TA | ICU | 159 | 1.6 | 53% | Not documented |